Genmab A/S
CSE:GMAB
Genmab A/S
CSE:GMAB
Price:
1 957.5 DKK
0.05%
Market Closed
Updated:
May 1, 2024
Genmab A/S
Operating Income
|
Genmab A/S
Operating Income Peer Comparison
Comparables:
ZEAL
ASND
B
BAVA
BIOPOR
SANION
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Operating Income
kr5.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
31%
|
CAGR 10-Years
54%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Operating Income
-kr561.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-12%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Operating Income
-€447.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Operating Income
kr2.1B
|
CAGR 3-Years
75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
51%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Operating Income
-kr60.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-12%
|
|
|
Saniona AB
STO:SANION
|
Operating Income
-kr79.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
See Also
What is Genmab A/S's Operating Income?
Operating Income
5.3B
DKK
5.3B
DKK
Based on the financial report for Dec 31, 2023, Genmab A/S's Operating Income amounts to 5.3B DKK.
What is Genmab A/S's Operating Income growth rate?
Operating Income CAGR 10Y
54%
54%
Over the last year, the Operating Income growth was -16%. The average annual Operating Income growth rates for Genmab A/S have been -6% over the past three years , 31% over the past five years , and 54% over the past ten years .
You don't have any saved screeners yet
